135 related articles for article (PubMed ID: 23554843)
1. Increased expression of the androgen receptor with p300 and interleukin-6 coactivators compensate for oligonucleotide suppression of bcl-2: no increased CREB binding protein or interleukin-4 expression.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2013 Apr; 5(2):85-93. PubMed ID: 23554843
[TBL] [Abstract][Full Text] [Related]
2. In LNCaP cells enhanced expression of both androgen receptor and costimulatory protein p300 compensate for antisense oligonucleotide suppression of bcl-2.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2011 Dec; 3(6):243-50. PubMed ID: 22164193
[TBL] [Abstract][Full Text] [Related]
3. Oligonucleotide suppression of bcl-2 in LNCaP cells is compensated by increased androgen sensitivity, p53 and oncogene activity, and suppressed caspase-3.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2013; 30(3):599. PubMed ID: 23677569
[TBL] [Abstract][Full Text] [Related]
4. In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
Ther Adv Urol; 2011 Apr; 3(2):51-7. PubMed ID: 21869905
[TBL] [Abstract][Full Text] [Related]
5. Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Sep; 29(3):2284-90. PubMed ID: 22038727
[TBL] [Abstract][Full Text] [Related]
6. Effects of BCL-2 suppression by antisense oligonucleotides on additional regulators of apoptosis compensatory change in non-targeted protein expression.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2011; 25(5):725-32. PubMed ID: 21753125
[TBL] [Abstract][Full Text] [Related]
7. No compensation in VEGF expression follows antisense suppression of BCL-2 activity.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2012; 26(6):937-40. PubMed ID: 23160675
[TBL] [Abstract][Full Text] [Related]
8. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
[TBL] [Abstract][Full Text] [Related]
9. Additional compensatory mechanisms altering antisense oligonucleotide suppression of BCL2: effects upon AKT1 and STAT3.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2014; 28(5):867-70. PubMed ID: 25189901
[TBL] [Abstract][Full Text] [Related]
10. Androgen Receptor Coactivators in Regulation of Growth and Differentiation in Prostate Cancer.
Culig Z
J Cell Physiol; 2016 Feb; 231(2):270-4. PubMed ID: 26201947
[TBL] [Abstract][Full Text] [Related]
11. Enhanced expression of bcl-2 following antisense oligonucleotide mediated growth factor deprivation.
Rubenstein M; Chou P; Mirochnik Y; Guinan P
Med Oncol; 1997 Mar; 14(1):23-9. PubMed ID: 9232607
[TBL] [Abstract][Full Text] [Related]
12. Bax expression remains unchanged following antisense treatment directed against BCL-2.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2011 Sep; 28(3):852-8. PubMed ID: 20422317
[TBL] [Abstract][Full Text] [Related]
13. Suppression of BCL2 by Antisense Oligonucleotides and Compensation by Non-Targeted Genes May Enhance Tumor Proliferation.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2015; 29(6):687-93. PubMed ID: 26546525
[TBL] [Abstract][Full Text] [Related]
14. p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6.
Debes JD; Comuzzi B; Schmidt LJ; Dehm SM; Culig Z; Tindall DJ
Cancer Res; 2005 Jul; 65(13):5965-73. PubMed ID: 15994976
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antisense oligonucleotides have activity comparable to monospecifics in inhibiting expression of BCL-2 in LNCaP cells.
Rubenstein M; Guinan P
In Vivo; 2010; 24(4):489-93. PubMed ID: 20668314
[TBL] [Abstract][Full Text] [Related]
16. No compensation in CD44 stem cell marker following BCL-2 suppression by antisense oligonucleotides.
Rubenstein M; Hollowell CM; Guinan P
In Vivo; 2013; 27(2):251-6. PubMed ID: 23422486
[TBL] [Abstract][Full Text] [Related]
17. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of androgen receptor coactivators in prostate cancer.
Culig Z; Comuzzi B; Steiner H; Bartsch G; Hobisch A
J Steroid Biochem Mol Biol; 2004 Nov; 92(4):265-71. PubMed ID: 15663989
[TBL] [Abstract][Full Text] [Related]
19. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
[TBL] [Abstract][Full Text] [Related]
20. Differentiated prostatic antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against BCL-2 and EGFR.
Rubenstein M; Hollowell CM; Guinan P
Med Oncol; 2012 Jun; 29(2):835-41. PubMed ID: 21573974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
